Antonio Pinto

29PUBLICATIONS
122CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Sep 16, 2026
T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.

|Apr 10, 2026
A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma.

Gabriele Gugliotta, Lisa Argnani, Martina Cantelli

|Jan 10, 2026
Nodal Marginal Zone Lymphoma with Prominent Expansion of PD-1+ T-Follicular Helper Cells: A Persistent Diagnostic Challenge with a Heterogeneous Mutational Architecture.

Stefania Crisci, Annarosaria De Chiara, Maria Oro

|Dec 24, 2025
Health-Related Quality of Life and Symptom Burden in Patients with Diffuse Large B-Cell Lymphoma Before Treatment with Tafasitamab and Lenalidomide: An Ad Hoc Analysis of Italian Real-World Data from the PRO-MIND Study.

Pier Luigi Zinzani, Nicola Battaglia, Mario Lapecorella

|Nov 04, 2025
Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B-Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts.

Antonio Pinto, Carmelo Carlo-Stella, Monia Marchetti

|Aug 14, 2025
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.

Alex F Herrera, Stephen M Ansell, Pier Luigi Zinzani

Pageof 5

Frequent Collaborators

10 joint publications

Rosaria De Filippi

8 joint publications

Pierluigi Zinzani

6 joint publications

Paolo Corradini

5 joint publications

Luca Arcaini